Adicet Bio Inc. (ACET), a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has key clinical trial events to watch in 2025.
The company has two investigational drugs in clinical development - ADI-001 and ADI-270.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com